کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2566064 | 1128073 | 2008 | 4 صفحه PDF | دانلود رایگان |
BackgroundThe N-methyl-d-aspartate (NMDA) receptor antagonist phencyclidine (PCP)-induced cognitive deficits have been used as an animal model for schizophrenia. This study was undertaken to determine whether the antibiotic drug minocycline could improve PCP-induced cognitive deficits in mice.MethodsSaline (10 ml/kg/day, s.c., once daily on day 1–5, 8–12) or PCP (10 mg/kg/day, s.c., once daily on day 1–5, 8–12) were administered to mice for 10 days. Subsequently, vehicle (10 ml/kg/day, i.p.) or minocycline (4.0 or 40 mg/kg/day, i.p.) was injected for 14 consecutive days. One day after the final injection, a novel object recognition test was performed.ResultsPCP-induced cognitive deficits in mice were significantly improved by subsequent subchronic (14 days) administration of minocycline (40 mg/kg), but not minocycline (4.0 mg/kg).ConclusionsThis study suggests that minocycline could be a potential therapeutic drug for cognitive deficits in schizophrenic patients.
Journal: Progress in Neuro-Psychopharmacology and Biological Psychiatry - Volume 32, Issue 2, 15 February 2008, Pages 336–339